E

EuBiologics Co Ltd
KOSDAQ:206650

Watchlist Manager
EuBiologics Co Ltd
KOSDAQ:206650
Watchlist
Price: 14 130 KRW 2.24% Market Closed
Market Cap: 517.4B KRW
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
-3%
Revenue
Forecast
-1%
Operating Income
Forecast
+10%
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
EuBiologics Co Ltd

Wall Street analysts forecast EuBiologics Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EuBiologics Co Ltd is 17 850 KRW with a low forecast of 16 160 KRW and a high forecast of 19 950 KRW.

Lowest Forecast
Wall Street Target
16 160 KRW
14% Upside
Average Forecast
Wall Street Target
17 850 KRW
26% Upside
Highest Forecast
Wall Street Target
19 950 KRW
41% Upside
Lowest
Price Target
16 160 KRW
14% Upside
Average
Price Target
17 850 KRW
26% Upside
Highest
Price Target
19 950 KRW
41% Upside
EuBiologics Co Ltd Competitors:
Price Targets
J
600201
Jinyu Bio-Technology Co Ltd
2% Upside
NBIX
Neurocrine Biosciences Inc
16% Upside
INSM
Insmed Inc
8% Upside
OPK
OPKO Health Inc
174% Upside
J
600201
Jinyu Bio-Technology Co Ltd
2% Upside
NBIX
Neurocrine Biosciences Inc
16% Upside
INSM
Insmed Inc
8% Upside
OPK
OPKO Health Inc
174% Upside
IMTX
Immatics NV
111% Upside
ABNX
Abionyx Pharma SA
189% Upside
A
ADOC
Adocia SA
88% Upside
IMNM
Immunome Inc
161% Upside

Revenue
Forecast

Revenue Estimate
EuBiologics Co Ltd

For the last 10 years the compound annual growth rate for EuBiologics Co Ltd's revenue is 41%. The projected CAGR for the next 3 years is 15%.

41%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
EuBiologics Co Ltd

The compound annual growth rate of EuBiologics Co Ltd's operating income for the next 3 years is 17%.

N/A
Past Growth
17%
Estimated Growth
Estimates Accuracy
12%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
EuBiologics Co Ltd

The compound annual growth rate of EuBiologics Co Ltd's net income for the next 3 years is 34%.

N/A
Past Growth
34%
Estimated Growth
Estimates Accuracy
-16%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EuBiologics Co Ltd's stock price target?
Price Target
17 850 KRW

According to Wall Street analysts, the average 1-year price target for EuBiologics Co Ltd is 17 850 KRW with a low forecast of 16 160 KRW and a high forecast of 19 950 KRW.

What is EuBiologics Co Ltd's Revenue forecast?
Projected CAGR
15%

For the last 10 years the compound annual growth rate for EuBiologics Co Ltd's revenue is 41%. The projected CAGR for the next 3 years is 15%.

What is EuBiologics Co Ltd's Operating Income forecast?
Projected CAGR
17%

The compound annual growth rate of EuBiologics Co Ltd's operating income for the next 3 years is 17%.

What is EuBiologics Co Ltd's Net Income forecast?
Projected CAGR
34%

The compound annual growth rate of EuBiologics Co Ltd's net income for the next 3 years is 34%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 283,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.